Providing providers with relevant data on quality of care and profitability allows them to adjust their practices efficiently, said Erich Mounce, chief operating officer, OneOncology.
Providing providers with relevant data on quality of care and profitability allows them to adjust their practices efficiently, said Erich Mounce, chief operating officer, OneOncology.
Transcript
If a practice isn’t doing well on cost savings or achieving high-quality care, how does OneOncology approach adjusting provider practices?
Well, I think the beauty of OneOncology is it’s not this cookbook process. It’s not—here’s our only way to do it and if you don’t do it this way, we come hit you with a club. I think it’s a variation of themes. We’ve got some practices—they’re really restrict regimens. We have some practices that have a little bit more selection of preferred regimens. It’s an education process and a rapid learning cycle of how that data is recirculated back. So, the first thing we do is sort of measure where they are and then start to feedback data. Then we also show them if they would adhere a little bit more to this pathway or perform a little bit better under this contract, look how that will affect either your compensation or profitability. So, it’s really taking all of that data, and constantly feeding back accurately and allowing the doctors to buy into that. That really does tend to move physician behavior a lot more than us just saying; you guys aren’t doing well—you need to do it this way.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More